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L-carnitine has received increasing attention,
mainly because of its beneficial effects on ischemic
tissues, including myocardium and skeletal mus-
cle.1-5 One of the most potent derivatives of L-car-
nitine is propionyl-L-carnitine (PLC), a naturally
occurring short-chain fatty acid ester of carnitine.6
PLC, when given intravenously to patients with
severe peripheral arterial disease, is more effective
than L-carnitine at improving the walking capacity
of patients with intermittent claudication.7,8
The mechanism by which PLC improves cardiac
or skeletal muscle function during ischemia is not fully
known, but it is thought to involve a direct metabol-
ic effect of the compound on the muscle.9-11 PLC can
be readily transported into the mitochondria, where it
is converted into free carnitine and propionyl coen-
zyme A (CoA).6 Within the mitochondria, propionyl
CoA can be converted to succinyl CoA and thereafter
to succinate, an intermediary of the citric acid cycle.6
Through this anaplerotic mechanism, PLC may pro-
vide additional substrates for energy production to
the ischemic muscle.12 In tissues with decreased
adenosine triphosphate (ATP) levels, such as occurs
after ischemia or cardiac hypertrophy, treatment with
PLC significantly elevates the  ATP:ADP ratio.11
Moreover, magnetic resonance spectroscopy studies
have shown decreased phosphocreatine recovery
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trast, PLC had significantly less effect on deendothelialized arteries, increasing diameter
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dency of this compound. Blockade of nitric oxide did not inhibit this vasodilation, with
the half-maximal response occurring at 8.6 ± 7 m mol/L, increasing diameter 85% ± 8%
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ished in the presence of indomethacin, which dilated arteries only 53% ± 18% at 100
m mol/L (P < .01 vs. intact; P > .05 vs. denuded).
Conclusion: PLC is an endothelium-dependent vasodilator, the mechanism of which is
partially mediated by prostaglandin synthesis, not nitric oxide. The beneficial effects of
this compound may, in part, be related to vasodilation and enhanced blood flow. (J Vasc
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times in leg muscles of patients with claudication pre-
viously supplemented with PLC.13
An alternative mechanism to explain both cardiac
improvement after myocardial ischemia and increased
walking distance of patients with claudication after
PLC supplementation is an effect of PLC on the vas-
culature and tissue perfusion. A direct effect of PLC
treatment improving vascular patency after an ischemic
event has been demonstrated in myocardium.14 In the
dog hind limb, perfusion of a physiological level of
PLC caused a 130% increase in blood flow, suggesting
that PLC has a direct vasodilatory effect.15 To date, no
studies have examined the effect of PLC on human
arteries. In this study, we hypothesized that PLC is a
vasodilator and tested this with exogenous administra-
tion of PLC to isolated human arteries in vitro by
means of a specialized arteriograph system that
allowed for control of intravascular pressure and con-
tinual measurement of lumen diameter. In addition,
we assessed the contribution of the endothelium to
mediating these vasoactive effects, because carnitine
has been shown to be an important intracellular medi-
ator of endothelial cell metabolism.16
MATERIALS AND METHODS
Patients. This investigation was approved by
the institutional review board at Oregon Health
Sciences University. Informed consent was obtained
from each patient. All arteries used for experimenta-
tion were obtained from patients undergoing lower-
extremity arterial surgery. Most of the patients were
men (15 of 19; 79%) and had a history of hyperten-
sion (15 of 19 total, men and women). The average
age was 71.5 ± 1.5 years. All patients had sympto-
matic arterial occlusive disease.
Preparation of arterial segments and denuda-
tion. All arteries (n = 19) used for experimentation
were taken from lower-extremity skin and subcuta-
neous fat biopsies obtained from patients undergoing
lower-extremity vascular surgery. A small piece (3.0 cm
· 2.0 cm · 1.0 cm) of skin and fat was removed from
the edge of the surgical incisions, placed in cold (4°C)
oxygenated physiological saline solution (PSS), and
immediately brought to the laboratory. For the sake of
consistency, biopsies were taken from the groin area
only. Small subcutaneous arteries (inner diameter, 90
to 200 m m) were carefully dissected from the subcuta-
neous fat with the aid of a dissecting microscope.
Because of the small size of the vessels, differentiation
between veins and arteries can be difficult. Therefore,
arteries were identified by comparison with adjacent
parallel veins, which are larger and have visibly thinner
walls (although this method of selection is not fool-
proof, once the vessels were mounted in the arterio-
graph chamber and pressurized to 50 mm Hg, veins
could be clearly distinguished, because they did not
hold pressure well and had a balloon-like appearance).
Arteries were carefully dissected and cleared of extra-
neous fat and connective tissue and transferred either
directly into one of the arteriograph chambers or to a
dissecting dish for endothelial denudation.
Endothelial denudation was accomplished with a
previously published technique,17 which we have found
effective. Briefly, the vessel to be denuded was trans-
ferred to a special dissecting dish containing several
human hairs of varying diameters (50 to 100 m m),
approximately 1.0 cm in length, with one end attached
by means of silicon epoxy to the base of the dish for sta-
bility. The artery was carefully slipped onto the free end
of an appropriately sized hair and pulled over the hair
two to three times, thus removing the endothelial cells
without damaging the surrounding smooth muscle.
The adequacy of this method has been verified by  scan-
ning electron microscopy and has been used successful-
ly on numerous occasions.17,18 After denudation, the
artery was transferred into one of the arteriograph
chambers. Successful denudation in these experiments
was tested with lack of dilation to acetylcholine.
Pressurized arteriograph system and measure-
ment of lumen diameter. The arteriograph (Living
Systems, Burlington, Vt) consisted of two 20 mL
chambers, with inlet and outlet ports to allow for
superfusion of the arteries with PSS and for the
application of drugs. The superfusate (PSS) was con-
tinuously recirculated from a 50 mL reservoir and
pumped via a peristaltic pump through a heat
exchanger to warm the PSS to 37°C before it
entered the arteriograph chamber. The PSS was aer-
ated in the reservoir with a mixture of 10%O2-
5%CO2-85%N2 to maintain a constant pH of 7.4 ±
0.05, PO2 of 103 mm Hg, and PCO2 of 34 mm Hg.
Each of the two arteriograph chambers contained
a set of proximal and distal glass microcannula (tip, 20
m m) attached to maneuverable bulkheads, to which
an artery was mounted, secured with single strands of
nylon suture (diameter, 20 m m), and perfused with
oxygenated PSS. The proximal cannula was attached
to an in-line pressure transducer and servo system that
continually measured and adjusted transmural pres-
sure (TMP). Each distal cannula was connected to a
stopcock, which was turned off during the experiment
so that there was no flow through the vessel. After
mounting one artery in each of the arteriograph
chambers, the arteries were pressurized by opening
the proximal stopcock. 
Once both arteries were cannulated and pressur-
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ized, the arteriograph was transferred to an inverted
microscope with an attached video camera and
monochrome monitor. Each cannulated artery was
suspended on bulkheads just above an optical win-
dow in the bottom of the chamber, which allowed
for viewing of the artery and electronic measurement
of lumen diameter. The transilluminated image of the
artery on the video monitor (only one artery can be
viewed at a time) was used to electronically deter-
mine the dimensions of the artery.19 The output
from the video camera was analyzed by a video
dimensional analysis system, in which the optical
density of the vessel wall is used to initiate and ter-
minate a voltage ramp, the amplitude of which is
proportionate to inner diameter.20 The output (ana-
log voltages) from the video dimension analyzer and
the pressure controller was connected to an IBM
compatible 386 computer through a serial data
acquisition system (Dataq, Akron, Ohio), permitting
the recording of dynamic responses in diameter and
TMP, similar to a chart recorder. 
Drugs and solutions. The superfusate and 
perfusate for all experiments consisted of a phosphate-
based bicarbonate buffer (Ringer’s PSS), the 
ionic composition of which was (mmol/L): NaCl
119.0, NaCHO3 24.0, KCl 4.7, KH2PO4 1.18,
MgSO4·7H2O 1.17, CaCl2 1.6, EDTA 0.026, and
glucose 5.5. PSS was made each week and stored with-
out glucose at 4°C. The appropriate amount of glucose
was added before each experiment. Norepinephrine
(NE) and indomethacin were purchased from Sigma
Chemical (St. Louis, Mo) and made fresh daily as stock
solutions of 10-2 mol/L, 10-3 mol/L, and 10-4 mol/L.
Nitro-L-arginine (L-NNA) and papaverine were also
purchased from Sigma and made each week as stock
solutions (10-2 mol/L) and stored at 4°C. The PLC
was a gift of Sigma Tau Pharmaceuticals (Gaithersburg,
Md) and was mixed fresh as a stock solution of 10-2
mol/L before each experiment.
Data calculations and statistical analysis. The
vasodilatory response to PLC was determined at
each concentration of PLC as a percent dilation
from the baseline diameter in NE, with the fully
relaxed diameter in papaverine as the maximum, by
means of the equation: 
(f PLC – f NE) ÷ (f max – f NE ) · 100;
where f max = fully relaxed diameter in 10-4
mol/L papaverine; f PLC = diameter measured after
that concentration of PLC; and f NE = diameter after
precontraction with NE. 
The IC50 values for each artery were determined
by plotting the concentration-response curves on a
logarithmic scale and extrapolating from a best-fit
line between 20% and 80% of the maximal dilation.
The IC50 was determined to be the value at which
the agonist produced 50% of the maximal response
(ie, IC50). The n value on each graph represents
artery number. All results are expressed as mean ±
SE. Differences at each concentration of PLC and
IC50 value, between intact and denuded and intact
and in the presence of indomethacin or L-NNA,
were determined by means of analysis of variance,
which was considered significant at P .05. 
Experimental protocols
Dependence of propionyl-L-carnitine-induced
vasodilation on the presence of the endothelium.
Arteries with and without endothelium were equili-
brated in PSS at TMP of 50 mm Hg for 1 hour.
Because these arteries do not possess intrinsic tone,
as determined from previous studies18 and experi-
ence with these arteries, an intermediate concentra-
tion of NE was added to the bath to contract the
arteries 30% to 50% of maximum. Arteries denuded
of endothelium were given 10 m mol/L acetylcholine,
an endothelium-dependent vasodilator, to test for
successful denudation (ie, lack of dilation to acetyl-
choline). The acetylcholine was washed out of the
bath, and the arteries again contracted with an inter-
mediate concentration of NE. PLC (1 to 100
m mol/L) was then added to the bath, and the diam-
eter was recorded at each concentration after a stable
diameter was attained, approximately 20 minutes. 
Dependence of propionyl-L-carnitine-induced
vasodilation on nitric oxide. To investigate the
involvement of endothelial nitric oxide (NO) synthe-
sis in mediating the vasoactive effects of PLC, anoth-
er group of arteries was incubated for 20 minutes in
0.3 mmol/L L-NNA, a potent inhibitor of NO syn-
thetase. The arteries were contracted with an inter-
mediate concentration of NE and PLC cumulatively
added to the bath, as described.
Dependence of propionyl-L-carnitine-induced
vasodilation on prostaglandins. To investigate the
involvement of prostaglandins in mediating the vasoac-
tive effects of PLC, a separate group of arteries was
incubated for 20 minutes in 10 m mol/L indomethacin,
an inhibitor of prostaglandin synthesis. The arteries
were then contracted with an intermediate concentra-
tion of NE and PLC cumulatively added to the bath,
as described.
At the end of each experiment, 0.1 mmol/L
papaverine was added to the bath, and a fully relaxed
diameter was recorded.
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RESULTS
Dependence of propionyl-L-carnitine-induced
vasodilation on the presence of the endothelium.
Addition of PLC to intact arteries caused concentra-
tion-dependent vasodilation, with the half maximal
response (IC50) occurring at 2.9 ± 1.2 m mol/L. At the
highest concentration of PLC (100 m mol/L), arteries
dilated 91% ± 5%. In contrast, PLC had significantly
less effect on arteries denuded of endothelium, with
the half-maximal response occurring at more than 100
m mol/L. At the highest concentration of PLC, denud-
ed arteries dilated 24% ± 11%. A diameter tracing of
one intact and one denuded artery demonstrating the
dilation to PLC is shown in Figs 1 and 2.
Dependence of propionyl-L-carnitine-induced
vasodilation on nitric oxide. The presence of L-
NNA had little effect on the vasodilation to PLC, and
the half-maximal response to PLC occurred at 8.6 ±
7 m mol/L (P > .05 vs. intact). These arteries dilated
85% ± 8% from baseline, similar to intact arteries.
Dependence of propionyl-L-carnitine-induced
vasodilation on prostaglandins. The presence of
indomethacin significantly decreased the sensitivity
and maximal dilation to PLC, compared with intact
arteries. The half-maximal response of arteries in the
presence of PLC was similar to that of denuded arter-
ies and was undeterminable at more than 100
m mol/L. The maximal dilation to PLC of arteries in
the presence of indomethacin was 53% ± 18% (P <
.05 vs. intact; P > .05 vs. denuded). The concentra-
tion-response to PLC of intact, intact and in the pres-
ence of L-NNA or indomethacin, and denuded arter-
ies is shown in Fig 3. A graph of the maximum per-
cent dilation of these arteries is shown in Fig 4. 
Response of arteries to maximum dilation in
papaverine
All arteries dilated to 0.1 mmol/L papaverine
and returned diameter to baseline. The average
baseline diameter for all arteries was 154 ± 7 m m vs.
161 ± 7 m m in papaverine (P > .05).
DISCUSSION
PLC has a vasodilatory effect on small, human
subcutaneous arteries precontracted with NE. Most
of this effect was endothelium-dependent and par-
tially mediated by prostaglandins, because arteries
either denuded of endothelium or in the presence of
indomethacin had significantly diminished dilation to
PLC. In contrast, arteries in the presence of L-NNA,
a compound known to inhibit NO synthesis, dilated
to PLC in a manner similar to intact arteries, indicat-
ing that production of NO was not likely involved in
mediating the vasodilatory effects of PLC.
Although the response to PLC appeared to be
mostly endothelium-dependent, deendothelialized
arteries did dilate to PLC at the higher concentra-
tions; however, the response was significantly dimin-
ished compared with that of intact arteries. This dila-
tion of denuded arteries suggests that there may be
some effect of PLC on the vascular smooth muscle.
Although arteries in the presence of indomethacin
also had a significantly diminished response to PLC
compared with intact arteries without indomethacin,
these arteries did dilate at the higher concentrations,
similarly to the denuded arteries. This effect may also
be a reflection of the vascular smooth muscle compo-
nent. Along these lines, other investigators have
found that another L-carnitine derivative, the iso-
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Fig 1. Diameter tracing of an intact human subcutaneous artery contracted with norepi-
nephrine and given increasing concentrations of propionyl-L-carnitine. Note that propionyl-L-
carnitine caused concentration-dependent vasodilation of this artery.
propyl ester of palmitoyl-L-carnitine, caused vasodila-
tion of the coronary and mesenteric circulations that
was shown to be caused by a direct effect on the
smooth muscle.21,22
The overall effect of L-carnitine and its deriva-
tives appears to be moiety specific. For example,
PLC increases the walking capacity of patients with
claudication to a greater extent than L-carnitine.8 In
the vasculature, palmitoyl-L-carnitine affects mem-
brane fluidity and has been shown to cause dimin-
ished endothelium-dependent vasodilation, whereas
the isopropyl ester of palmitoyl-L-carnitine causes
vasodilation.21,22 In the present study, we found that
PLC caused vasodilation of human arteries that
appeared to be mostly mediated by endothelial
prostaglandin production. Given the differential
effects of these various moieties, it would be inter-
esting to compare the vasoactive effects of L-carni-
tine and its derivatives in these human arteries as
well. Although the focus of this study was on PLC
and its specific effects on the cellular components
that mediate arterial diameter, further investigation
into these specific moieties is warranted.
The specific effect of PLC on the endothelium and
prostaglandin synthesis in this study is not defined.
The mechanism may involve calcium hemostasis or
synthesis of key prostaglandin precursors. It has been
found that after stimulation with an ionophore such as
A23817, rat peritoneal macrophages incubated with
PLC release high levels of PGI2.23 A role for PLC in
prostaglandin synthesis is also suggested by observa-
tions in isolated hepatocytes, indicating that PLC can
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Fig 3. Graph of the concentration-response curves to
propionyl-L-carnitine of intact, intact and in the presence
of 0.1 mmol/L L-NNA or 10.0 m mol/L indomethacin,
and denuded human arteries. Note that propionyl-L-car-
nitine caused concentration-dependent vasodilation in
intact arteries, but had little effect on deendothelialized
arteries. Arteries in the presence of L-NNA dilated to a
similar degree as intact arteries; however, the presence of
indomethacin significantly reduced this vasodilation. *P <
.05; **P < .01 vs. intact.
Fig 2. Diameter tracing of a denuded human subcutaneous artery contracted with norepi-
nephrine and given increasing concentrations of propionyl-L-carnitine. Note that propionyl-L-
carnitine had considerably less effect on the diameter of this artery.
enhance formation of arachidonic acid, a key interme-
diate in prostaglandin synthesis, from linoleic acid.24
In addition, Bertelli et al have shown that PLC can
prevent endothelin- and carrageenin-induced throm-
bosis in the rat tail artery through a mechanism involv-
ing prostaglandin synthesis.25
The arteries used in this study were small subcu-
taneous fat arteries obtained from patients undergo-
ing lower-extremity vascular surgery, all of whom had
peripheral vascular disease. Although these patients
did not provide healthy arteries, this study demon-
strates that PLC can cause vasodilation of arteries iso-
lated from patients with peripheral vascular disease, a
patient population that is similar to the one which
would receive PLC treatment. Table I shows the
patient demographics for each group of arteries
obtained for this study. The only pathology that we
feel may affect interpretation of the results is type 2
diabetes mellitus (DM), found in 6 of 19 patients.
Because we have previously demonstrated that DM
specifically affected basal production of endothelial
NO18 without affecting smooth muscle cell respons-
es, we used these arteries only in the endothelial
denuded and L-NNA groups. By using DM arteries
in these groups, we were certain that the effects
noted were not caused by the pathology of the artery.
DM arteries in the presence of L-NNA dilated to a
similar degree as intact nondiabetic arteries, further
demonstrating that DM did not likely influence the
response to PLC. All other pathologies (hyperten-
sion, history of smoking, etc) were consistent among
the groups and therefore did not likely influence the
response of one group versus another. 
In conclusion, PLC was shown to cause vasodi-
lation of human subcutaneous arteries, an effect that
appeared mostly mediated by endothelial produc-
tion of prostaglandins, but also appeared to have a
modest smooth muscle cell component at higher
concentrations. Therefore, the beneficial cardiovas-
cular effects of this compound may, in part, be relat-
ed to vasodilation and enhanced blood flow.
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